The study and its comparison
The randomized research included 753 participants. Its population was adults with quiescent crohn disease across two trials; 738 evaluated. The comparison used omega-3 free fatty acids 4 g daily versus placebo, with observation over up to fifty-eight weeks. [1]
One-year relapse estimates were 31.6% versus 35.7% in EPIC-1 and 47.8% versus 48.8% in EPIC-2. Neither comparison was significant. Other Crohn treatments were not permitted within the study protocol. [1]
What the finding establishes
The enrolled and evaluated counts differ and should remain explicit. These were remission-maintenance trials, not tests of treatment for an acute flare. A general anti-inflammatory rationale is insufficient when relapse outcomes are negative. The protocol is not a reason to discontinue prescribed maintenance care. Funding and complete conflicts were not established from the retrieved abstract. [1]
A hypothetical distinction
Imagine a laboratory mechanism suggests less inflammation but two trials find no reduction in relapse. Clinical maintenance efficacy has not been demonstrated.
| Detail | Interpretation |
|---|---|
| Measured outcome | Keep the endpoint specific |
| Study preparation | Not every retail product |
| Remaining uncertainty | Not resolved by a mechanism |
Sources for this article
- Omega-3 free fatty acids for the maintenance of remission in Crohn disease: the EPIC Randomized Controlled Trials.
Source consulted: 2026-09-19. This is a reference resource, not a claim that we conducted the studies or tested a product.